Activation of Inward Rectifier Potassium Channels Accelerates Atrial Fibrillation in Humans

Evidence for a Reentrant Mechanism

Felipe Atienza, MD, PhD; Jesús Almendral, MD, PhD; Javier Moreno, MD; Ravi Vaidyanathan, MS; Arkadzi Talkachou, MS; Jérôme Kalifa, MD; Angel Arenal, MD; Julian P. Villacastín, MD, PhD; Esteban G. Torrecilla, MD, PhD; Ana Sánchez, MD; Robert Ploutz-Snyder, PhD; José Jalife, MD; Omer Berenfeld, PhD

Background—It is unclear whether atrial fibrillation (AF) drivers in humans are focal or reentrant. To test the hypothesis that functional reentry is involved in human AF maintenance, we determined the effects of adenosine infusion on local dominant frequency (DF) at different atrial sites. By increasing inward rectifier potassium channel conductance, adenosine would increase DF of reentrant drivers but decrease it in the case of a focal mechanism.

Methods and Results—Thirty-three patients were studied during AF (21 paroxysmal, 12 persistent) using recordings from each pulmonary vein–left atrial junction (PV-LAJ), high right atrium, and coronary sinus. DFs were determined during baseline and peak adenosine effect. In paroxysmal AF, adenosine increased maximal DF at each region compared with baseline (PV-LAJ, 8.03 ± 2.2 versus 5.7 ± 0.8; high right atrium, 7.2 ± 2.2 versus 5.4 ± 0.7; coronary sinus, 6.6 ± 1.1 versus 5.3 ± 0.7 Hz; P = 0.001) and increased the left-to-right DF gradient (P = 0.007). In contrast, in persistent AF, adenosine increased DF only in the high right atrium (8.33 ± 1.1 versus 6.8 ± 1.2 Hz; P = 0.004). In 4 paroxysmal AF patients, real-time DF mapping of the left atrium identified the highest DF sites near the PV-LAJ, where adenosine induced an increase in DF (6.7 ± 0.29 versus 4.96 ± 0.26 Hz; P = 0.008). Finally, simulations demonstrate that the frequency of reentrant drivers accelerates proportionally to the adenosine-modulated inward rectifier potassium current.

Conclusions—Adenosine accelerates drivers and increases frequency differently in paroxysmal compared with persistent human AF. The results strongly suggest that AF is maintained by reentrant sources, most likely located at the PV-LAJ in paroxysmal AF, whereas non-PV locations are more likely in persistent AF. (Circulation. 2006;114:2434-2442.)

Key Words: ablation ■ adenosine ■ atrium ■ fibrillation ■ Fourier analysis ■ reentry
Adenosine Infusions and Recording Protocol

A central venous bolus infusion of 12-mg adenosine was repeated up to 5 times during AF once all recording catheters were in a stable position. Figure 2 shows the timeline of infusion and recording protocol. Catheters remained at fixed positions in the HRA, CS, and PV-LAJ of the LSPV for the duration of all infusions. For every infusion, the Navistar mapping catheter was positioned randomly at a different PV-LAJ and at a high-frequency site in the posterior LA wall. A 5-second period before infusion and a 5-second period surrounding the longest RR interval at peak adenosine effect were analyzed.

Spectral Analysis

DF was determined as previously described. All signals were visually inspected, and spurious DFs were excluded or corrected. See the online-only Data Supplement for further details.

Radiofrequency Ablation of AF

After the adenosine infusion protocol, radiofrequency (RF) ablation was applied around the PVs, regardless of the spectral analysis results, aiming at terminating AF. In most patients, the technique used was circumferential LA ablation. In a subset of 6 patients, the ablation technique used was PV electrical isolation.

Statistical Analysis

Continuous variables are reported as mean±SD or median and interquartile range (IQR), depending on whether they were normally or nonnormally distributed. Categorical variables are reported as number and percentage. The effect of adenosine infusions on activation rate and regularity at each atrial region was compared using a 3-factor, mixed-model analysis of variance design that included 2 repeated-measures (within-subject) factors and 1 independent-measures factor. The 2 within-subject factors were time (baseline versus peak) and atrial sites (HRA, CS, PV-LAJ), and the independent-measures factor was AF type (paroxysmal versus persistent AF). The model used a priori pairwise contrasts comparing baseline and peak adenosine infusions within location and AF using Bonferroni correction for multiple comparisons. Statistical significance was established at=P<0.05.

Computer Simulations

We used a 5×5-cm² model with realistic human atrial kinetics with heterogeneous I\textsubscript{K,ACh} density and increasing the acetylcholine (ACh) concentration from 0.003 to 0.1 µmol/L, simulating the transition from baseline to peak adenosine. See the online Data Supplement for further details.

The authors had full access to the data and take full responsibility for their integrity. All authors have read and agree to the manuscript as written.

Figure 1. Left anterior oblique fluoroscopic view of heart and electrode positions during adenosine infusions: (1) tetrapolar catheter in the right atrium (HRA), (2) deflectable mapping catheter in the distal coronary sinus (CS), (3) decapolar circular mapping catheter at the PV-LAJ of the LSPV ostium, and (4) ablation catheter (Abl) at the right superior PV-LAJ.

Figure 2. Top, Timeline for each adenosine infusion (infusions 1 through 5) and recording (gray bars). Bottom, Representative surface ECG during the third infusion showing the analyzed time periods: baseline recording (0 to 5 seconds) and peak adenosine effect recording (38 to 43 seconds) as demonstrated by the presence of AV block.
Male, n (%) 15 (71) 10 (83) 0.66
Age, y 51.6
LV ejection fraction, % 61.5
Sustained AF duration, mo NA 17.9
Paroxysmal AF
(n=21)
Persistent AF
(n=12)
\(P\)

<table>
<thead>
<tr>
<th>Patient Characteristics</th>
<th>Paroxysmal AF</th>
<th>Persistent AF</th>
<th>(P)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>51.6±8.7</td>
<td>49.3±9.9</td>
<td>0.52</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>15 (71)</td>
<td>10 (83)</td>
<td>0.66</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>27.9±3.5</td>
<td>27.7±3.5</td>
<td>0.84</td>
</tr>
<tr>
<td>Structural heart disease</td>
<td>3 (14)</td>
<td>1 (8)</td>
<td>0.62</td>
</tr>
<tr>
<td>First AF episode, n (%)</td>
<td>&lt;1 y 5 (24)</td>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td></td>
<td>1–3 y 3 (14)</td>
<td>3 (25)</td>
<td>...</td>
</tr>
<tr>
<td></td>
<td>&gt;3 y 13 (62)</td>
<td>9 (75)</td>
<td>0.16</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>162±35.7</td>
<td>181±52.5</td>
<td>0.31</td>
</tr>
<tr>
<td>LA size, mm</td>
<td>38.4±6</td>
<td>46.6±4.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>LA area, cm²</td>
<td>18.4±5.8</td>
<td>37.2±13.9</td>
<td>0.03</td>
</tr>
<tr>
<td>RA area, cm²</td>
<td>15±2.8</td>
<td>23.5±12.8</td>
<td>0.01</td>
</tr>
<tr>
<td>LV ejection fraction, %</td>
<td>61.5±5.6</td>
<td>60±2.1</td>
<td>0.28</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>162±35.7</td>
<td>181±52.5</td>
<td>0.31</td>
</tr>
<tr>
<td>Antiarrhythmics used, n</td>
<td>2±0.6</td>
<td>2.2±0.9</td>
<td>0.55</td>
</tr>
<tr>
<td>Prior amiodarone treatment, n (%)</td>
<td>10 (48)</td>
<td>5 (42)</td>
<td>0.74</td>
</tr>
</tbody>
</table>

LV indicates left ventricular.

Results

Patients

Thirty-three patients (age, 51±9 years; 76% male) were studied during ongoing AF (21 paroxysmal, 12 persistent) before ablation. There were no clinical differences between paroxysmal and persistent AF patients (Table). However, persistent AF patients had significantly larger LA and RA areas and tended to have a longer history of AF. Twelve patients (6 paroxysmal, 6 persistent AF) presented with mild mitral regurgitation, but only 1 paroxysmal AF patient had moderate mitral regurgitation. No patient had significant left ventricular dysfunction, heart failure, or coronary artery disease.

On arrival at the electrophysiology laboratory, 20 of 21 paroxysmal AF (95%) and 0 of 12 persistent AF (0%) patients were in sinus rhythm. AF was induced during catheter manipulation in 5 of 21 patients (24%); AF was provoked by incremental CS pacing in the remaining 15 patients. Only 1 paroxysmal AF patient required reinduction as a result of incremental CS pacing in the remaining 15 patients. Only 1 paroxysmal AF patient had moderate mitral regurgitation. No patient had significant left ventricular dysfunction, heart failure, or coronary artery disease.

Adenosine Infusion

Overall, a total of 123 adenosine infusions were performed (median, 4 infusions per patient; IQR, 3). There was no significant difference (\(P=0.21\)) in the number of infusions between paroxysmal (median, 3; IQR, 3) and persistent (median, 5; IQR, 2) AF patients. The 12-mg adenosine bolus produced significant bradycardia or transient atrioventricular (AV) block in most patients (95%), with a median AV block duration of 4.4 seconds (IQR, 3.6 seconds). There was no significant difference (\(P=0.18\)) in the duration of adenosine-induced AV block between paroxysmal (median, 5.2 seconds; IQR, 1.9 seconds) and persistent AF patients (median, 3.3 seconds; IQR, 0.6 seconds). In 1 case, the first 12-mg bolus produced significant AV block (13.5 seconds) without clinical impact, but in subsequent boluses, doses were reduced to 6 mg, producing a mean of 7.7-second AV block episodes. Only 1 patient required an increase in the adenosine bolus dose (18 mg) to obtain the desired effect. One patient developed mild bronchospasm after the first adenosine bolus but recovered spontaneously and completely. The total time required to sequentially perform the proposed adenosine infusions and to record from all attempted PVs (from the baseline of the first infusion to the end of the last recording) was 15 minutes 37 seconds±7 minutes 8 seconds. Protocol duration was similar in paroxysmal (14 minutes 5 seconds±7 minutes 6 seconds) and persistent (17 minutes 47 seconds±8 minutes 5 seconds; \(P=0.44\)) AF patients. In a subset of patients (n=6), only mild conscious sedation was used.

Adenosine Accelerates AF Frequency

Of a total of 195 LA sites with simultaneous recordings for HRA and CS, both at baseline and after adenosine infusion, 29 were excluded because of poor signal quality. Twenty-eight and 27 patients had simultaneous recordings in the HRA and CS, respectively, during the first infusion. Twenty-three and 22 patients had recordings from those sites, respectively, during at least 2 infusions (up to 5). In 6 patients, no PV lasso recordings were obtained.

Figure 3 shows representative recordings illustrating the time course of the effect of adenosine on the activity of the LSPV in the same patient as in Figure 2. The data on top demonstrate that DF increases at 2 different locations in the PV-LAJ from ∼5 Hz at baseline to ∼6 Hz at the peak of the effect, followed by a return to approximate baseline values at recovery. The 3 power spectra of electrode pair 8,9 were extracted at specific time points indicated by the red arrows on the color-coded spectrogram presented at the bottom, which shows the temporal evolution of DF. Clearly, after a stable control period of ∼25 seconds, the DF at the LSPV increased from baseline to a peak value of 6.2 Hz, concomitant with AV block (see Figure 2). This was followed by a return to baseline 15 to 20 seconds after the peak effect. The relatively full return to baseline at both locations indicates DF stability for periods of at least 1 minute. Baseline DFs at the beginning of each of the 5 infusions fluctuated with an average standard deviation of 0.25 and 0.21 Hz in paroxysmal and persistent AF patients, respectively, with no temporal trend during the protocol.9 When we compared the DFs at baseline and at peak adenosine effect for the first 3 consecutive infusions at all sites and patients, we found no significant differences with time. Thus, the temporal stability of the DFs and reproducibility, at both baseline and peak adenosine effect, was validated in the LSPV, as well as in the HRA and CS.

As illustrated in Figure 4A, in paroxysmal AF patients, DF was somewhat higher in the PV-LAJ (5.7±0.8 Hz) than in the HRA and CS (5.4±0.7 and 5.3±0.7 Hz, respectively; \(P=NS\)). Upon adenosine infusion, the local DF increased in all regions compared with baseline (PV-LAJ, 8.03±2.2 versus 5.7±0.8 Hz; HRA, 7.2±2.2 versus 5.4±0.7 Hz; CS, 6.6±1.1 versus 5.3±0.7 Hz; \(P=0.001\)). However, the effect was much larger in the PV-LAJ, which resulted in a signifi-
cant left-to-right DF gradient ($P=0.007$). In general, patients with persistent AF demonstrated higher maximal baseline DFs (PV-LAJ, 6.9±1.1 Hz; HRA, 6.8±1.2 Hz; CS, 6.6±0.8 Hz) than paroxysmal AF patients ($P<0.001$). As shown in Figure 4B, adenosine infusion in persistent AF patients increased local DFs only in the HRA (8.3±1.1 versus 6.8±1.2 Hz; $P=0.004$). The increase in the PV-LAJ was not statistically significant (7.6±1.7 versus 6.9±1.1 Hz; $P=0.1$), and there was no change in the CS DF (6.6±0.7 versus 6.6±0.8 Hz; $P=NS$). When considering the ablation outcome in those patients, we observed no differences in DFs either at baseline or upon adenosine infusion between paroxysmal AF patients with versus without sinus rhythm conversion during RF ablation (Persistent AF patients were not analyzed because of the small sample size; see the online Data Supplement).

In 4 additional paroxysmal AF patients, the adenosine effect was measured at the primary and secondary DFmax sites in the LA (see Methods) that play an important role in AF maintenance. Maps of the LA were obtained using real-time DF analysis. We acquired 81±17 points per patient, 74% of which were valid. Figure 5 shows a representative example in which the AF frequency was relatively slow (25 Hz) and 3 DFmax sites were identified with a primary DF max site near the RIPV (red arrow). Figure 5B and 5C show that, although the adenosine infusion practically abolished the ventricular activity as detected by V5, the DF at the primary DF max site accelerated from 4.64 to 6.35 Hz. An additional adenosine infusion performed while measuring activity at the secondary DFmax sites also showed an increase in DF, but to a lesser extent. In this patient, the arrhythmia terminated during postmapping ablation at the primary DFmax site, demonstrating again its critical role in AF driver location. Compared with baseline, adenosine significantly accelerated the primary and secondary DFmax sites in these 4 patients from 4.96±0.26 to 6.7±0.29 Hz ($P=0.008$), demonstrating that the sites involved in the maintenance of AF are clearly affected by adenosine.
Computer Simulations
A simplified in silico 2-dimensional model of the atria was used to provide mechanistic insight into the effects of adenosine on DF\textsubscript{max} and the LA-to-RA DF gradient. The adenosine effect was simulated by activation of I\textsubscript{K,ACh}. Figure 6 shows consecutive snapshots during a simulation of paroxysmal AF at baseline (Figure 6A) and peak adenosine effect (Figure 6B). In Figure 6A, stable reentry in the left half of the sheet acted as the high-frequency source (a; DF\textsubscript{max} < 1 Hz) of waves that propagated toward the right (b; DF\textsubscript{max} < 4.4 Hz). In Figure 6B, I\textsubscript{K,ACh} activation increased the rotation frequency and consequently the DFs in the LA (15.9 Hz) and RA (9 Hz). When conditions of persistent AF were established and a reentrant source was simulated in the LA (see movie clips in the online Data Supplement), I\textsubscript{K,ACh} activation increased the DF in the LA (11 to 14.6 Hz) and unified the DFs in the RA from a range of 8.8 to 11 Hz during baseline to 9.8 Hz during I\textsubscript{K,ACh} activation. Overall, although the AF frequencies are somewhat higher in the simulations than in the patients, qualitatively, the numerical results demonstrate that I\textsubscript{K,ACh} activation by adenosine increases the source region DF and consequently the left-to-right frequency gradient in both paroxysmal AF (4.6 to 6.9 Hz) and persistent AF (2.2 to 4.8 Hz). In general, the degree of DF increase was significantly higher in paroxysmal AF (77% LA; 100% RA) compared with persistent AF (33% LA; 0% RA).

Dissociated PV Potentials
The response of dissociated PV potentials (DPVPs) to adenosine infusion (12-mg bolus) was assessed after PV isolation. DPVPs were observed in 4 patients (14%). We observed slow (cycle length >1200 ms) DPVPs at baseline in 2 paroxysmal and 1 persistent AF patients; rapid (cycle length <400 ms) DPVPs were observed in 1 paroxysmal patient. Figure 7 shows an example of a rapid DPVP (mean cycle length, 185 ms) after PV isolation and conversion to sinus rhythm.

During peak adenosine effect, there was a marked acceleration (mean cycle length, 120 ms) and regularization of the dissociated PV local activity, with a significant increase in DF from 6.68 Hz at baseline to 9.3 Hz at peak adenosine effect. In contrast, adenosine infusion transiently suppressed slow DPVPs in all patients, as illustrated by the example in Figure 8.

Discussion
The major finding of the present study is that, in humans, activation of I\textsubscript{K,ACh} channels by adenosine accelerates AF drivers and increases the excitation frequency differently in paroxysmal compared with persistent AF. In paroxysmal AF patients, adenosine infusion increases local DFs, particularly at the PV-LAJ region, amplifying a left-to-right frequency gradient. In persistent AF patients, DF is significantly higher than in paroxysmal AF patients in all atrial regions surveyed, with the highest adenosine increase in frequencies outside the PV region. As confirmed by computer simulations, adenosine-induced driver acceleration is strongly suggestive of a reentrant mechanism in both groups of AF patients. These results are a natural extension of our previous experimental and clinical studies\textsuperscript{2–6,9,15} and support the idea that AF in humans is maintained by high-frequency reentrant sources that can be accelerated by intravenous administration of adenosine. Final proof of this idea, however, requires a more direct demonstration of both high-frequency rotors in the human atria and their acceleration by adenosine.

AF Mechanisms
The mechanisms underlying AF maintenance in humans remain poorly understood. The multiple wavelet hypothesis led to the consensus that AF is the result of the random propagation of multiple wavelets across the atria.\textsuperscript{16} However, experimental studies suggest that at least some cases of AF may be maintained by high-frequency reentrant sources
(drivers), usually located in the posterior LA, that result in spatially distributed frequency gradients.\(^2\)–\(^6\) Recently, clinical studies have confirmed the existence of a hierarchical organization in the rate of activation of different regions in the atria of patients with paroxysmal and persistent AF.\(^7\)–\(^9\) Moreover, ablation of high-frequency sites results in AF termination in a significant proportion of patients with paroxysmal AF, confirming their role in the maintenance of AF in humans.\(^9\) To date, however, whether such sites are automatic, triggered, or reentrant remains unresolved. The present combined electrophysiological/pharmacological study was designed to address that issue specifically.

Adenosine Provides Mechanistic Insight in AF
Adenosine and ACh are known to activate the same Kir3.x subfamily of inward rectifier potassium channels through different signaling pathways.\(^17\) The current that arises from such activation is the same and called either \(I_{K,ACh}\) or \(I_{K,Ado}\), depending on whether ACh or adenosine is the agonist.\(^10\)–\(^11\)–\(^17\) By increasing \(K^+\) conductance in the atrium, both ACh and adenosine hyperpolarize the cell membrane, abbreviate the action potential duration and refractory period, and inhibit spontaneous pacemaker discharge, as well as early and delayed depolarizations.\(^10\)–\(^11\) Experimentally, ACh increases atrial activation frequency in a dose-dependent manner, with the effect being larger in LA than RA, leading to an increase in LA-to-RA frequency gradient.\(^15\) As with the simulations shown here (Figure 6), changes in rotor frequency were responsible for the changes in \(DF_{max}\).\(^15\) Thus, the adenosine-induced acceleration of \(DF_{max}\) points toward reentry as the mechanism of AF maintenance in the patients surveyed here and all but rules out an automatic or triggered mechanism.

Adenosine Amplifies DF Gradient in Paroxysmal AF
Because ablation at the highest-DF sites is associated with AF termination in 87% of paroxysmal AF,\(^9\) adenosine infusion during ongoing AF could be used as a diagnostic tool (see the online Data Supplement). Indeed, the present study shows that a baseline dominance of the LA is further enhanced by adenosine infusion and can potentially point to the location of the source. According to Sanders et al,\(^9\) the highest-DF sites were found in the PV-LAJ region at baseline in 60% of the cases, whereas upon adenosine infusion, the highest-DF sites were localized in the PV-LAJ region in the 76% of patients. Our preliminary results using high-density real-time DF mapping confirm the ability of adenosine to highlight sites driving paroxysmal AF that could be targeted for ablation (Figure 5). The left-to-right gradient in DFs is in agreement with prior reports.\(^7\)–\(^9\) Lazar et al\(^7\) demonstrated the presence of a similar gradient in paroxysmal human AF, confirming experimental results.\(^2\)–\(^6\) Regional disparities of spatial DF distribution between both studies exist, however. Although we found a regional maximal frequency gradient from the LA to RA with lowest DFs in the CS, Lazar et al\(^7\) found that DFs were lowest in the posterior RA and intermediate in the CS. This may be attributed to a different methodology. We obtained a single recording from the HRA, close to the interatrial septum, whereas Lazar et al considered an average value taken from 5 sites in the posterior RA. More extensive mapping studies may account for the differences found in the 2 studies. This is suggested by the agreement of our results with those of Sanders et al,\(^9\) who conducted high-density (126 ± 13 points per patient) frequency mapping of both atria and the CS during AF.\(^9\) Animal studies also support such an idea,\(^18\) which may explain why the highest DFs located in the right PVs can be followed by faster DFs in the RA than in the CS via rapid conduction through the Bachmann bundle. Similarly, Jais et al\(^19\) demonstrated slower and more organized activity in the distal CS that does not necessarily reflect the adjacent endocardial LA activity.

Adenosine Effect in Persistent AF
Patients with persistent AF demonstrated higher baseline DFs at each region compared with paroxysmal AF, but we found no spatiotemporal differences between mapped atrial sites. In this group, adenosine infusion increased local DFs only in the
HRA, without significant changes at other atrial sites. The acceleration in the HRA suggests that persistent AF also is maintained by high-frequency reentrant sources; however, such sources could be located at non-PV sites. Our data are consistent with those of other investigators who have reported a change in spatiotemporal organization in persistent AF.9,20,21 In contrast, Lazar et al7 did not find that persistent AF rates were any faster than paroxysmal AF rates, but they also reported a loss in spatial gradient due predominantly to an increase in the DF of the RA. When high-density mapping techniques were used, however, a left-to-right gradient also was observed in persistent AF patients. Sahadevan et al8 found the highest-frequency activity in the posterior LA in most patients with chronic AF undergoing intraoperative epicardial mapping, suggesting that the posterior LA may be the driving source maintaining chronic AF. Sanders et al,9 however, found that patients with permanent AF were more likely to have high-DF sites localized to other non-PV regions of the atria, including the RA.

The different spatial response to adenosine in paroxysmal versus persistent AF patients could be due to substrate remodeling in persistent AF. Atrial myocytes adapt to a chronic high rate by downregulating $I_{K_ACh}$ to counteract the shortening of the atrial effective refractory period resulting from electrical remodeling.22 $I_{K_ACh}$ downregulation is counteracted by an increase in $I_{K_1}$, which plays an important role in stabilization and acceleration of functional reentry.23 Up-regulation of $I_{K_1}$ in patients with persistent AF results in higher AF frequencies at baseline compared with paroxysmal AF patients. Therefore, as demonstrated by our computer simulations, persistent AF–induced downregulation of $I_{K_ACh}$ channels could result in a significantly blunted response to adenosine. Whether $I_{K_ACh}$ channel downregulation is chamber specific and accounts for the observed differences between paroxysmal and persistent AF warrants further investigation.

**Adenosine Effect on DPVPs**

We documented a differential response to adenosine infusion of DPVPs that depended on their rate. As noted by Marrouche et al,24 we observed that slow DPVPs were transiently abolished by adenosine, with complete recovery when the adenosine effect faded out, suggesting automaticity or trig-
gered activity as the responsible mechanism. In contrast, rapid dissociated activity within the circumferential area isolating the PV from the atrial body responded to adenosine infusion with cycle length shortening and an increase in local frequency and regularity (Figure 7). It is therefore reasonable to surmise that, in contrast to the slow DPVPs, these rapid sources represent rotors confined to the isolated portion of the PV-LAJ.

**Study Limitations**

The present study has several limitations. First, we cannot rule out the existence of higher-frequency areas outside the mapped regions, especially in persistent AF patients. Second, the effect of sedation on autonomic tone could influence the results. No differences were observed, however, between patients under deep sedation state and those under mild conscious sedation (data not shown). Third, a significant proportion of the paroxysmal AF episodes were induced, as in other studies on mechanisms or ablation of AF. Finally, proportions of the paroxysmal AF episodes were induced, as in other studies on mechanisms or ablation of AF. Finally, no differences were observed, however, between patients under deep sedation state and those under mild conscious sedation (data not shown).

**Sources of Funding**

This work was supported in part by grants from the Spanish Society of Cardiology, Biosense Webster, and Guidant, Inc (F.A.); NIH grants PO1 HL039707, RO1 HL070074, and RO1 HL060843 (J.J.); and American Heart Association Scientist Development Grant 0230311N (O.B.).

**Disclosures**

O.B., J.J., and R.V. have licensing agreements with Biosense Webster.

**References**

Radiofrequency ablation of high-frequency sites (drivers) results in atrial fibrillation (AF) termination in a significant proportion of patients, consistent with the role of such drivers in the maintenance of AF. However, it is unclear whether AF drivers in humans are focal (automatic or triggered) or reentrant. The answer to this question may lead to novel AF treatment strategies (either pharmacological or invasive). In the present study, we have determined the effects of adenosine infusion on local activation frequency at different sites of the fibrillating atria of patients and used computer simulations to help explain the results. Adenosine shortens refractoriness in the atrium, which accelerates some forms of reentry but suppresses automatic or triggered activity. As expected from a reentrant mechanism of AF drivers, adenosine infusion increased frequency primarily at sites that activated at the highest rate at baseline. In paroxysmal AF patients, adenosine suppresses automatic or triggered activity. As expected from a reentrant mechanism of AF drivers, adenosine infusion may be useful to help identify reentrant drivers to guide AF ablation.
Activation of Inward Rectifier Potassium Channels Accelerates Atrial Fibrillation in Humans: Evidence for a Reentrant Mechanism
Felipe Atienza, Jesús Almendral, Javier Moreno, Ravi Vaidyanathan, Arkazdi Talkachou, Jérôme Kalifa, Angel Arenal, Julian P. Villacastín, Esteban G. Torrecilla, Ana Sánchez, Robert Ploutz-Snyder, José Jalife and Omer Berenfeld

Circulation. 2006;114:2434-2442; originally published online November 13, 2006;
doi: 10.1161/CIRCULATIONAHA.106.633735
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2006 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/114/23/2434

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2006/11/13/CIRCULATIONAHA.106.633735.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/